StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVNFree Report) in a report released on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Trevena Stock Performance

TRVN stock opened at $3.94 on Friday. Trevena has a one year low of $3.35 and a one year high of $19.23. The firm’s fifty day moving average is $3.15 and its 200 day moving average is $1.35. The firm has a market cap of $3.35 million, a PE ratio of -1.47 and a beta of 1.03.

Trevena (NASDAQ:TRVNGet Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.36. The business had revenue of $0.33 million for the quarter. Research analysts predict that Trevena will post -32.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Trevena stock. Armistice Capital LLC purchased a new stake in Trevena, Inc. (NASDAQ:TRVNFree Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned approximately 4.61% of Trevena at the end of the most recent quarter. Institutional investors own 13.56% of the company’s stock.

About Trevena

(Get Free Report)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Featured Articles

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.